Vitro Biopharma, Inc. Quarterly Deferred Tax Assets, Operating Loss Carryforwards in USD from Q3 2022 to Q3 2023

Taxonomy & unit
us-gaap: USD
Description
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
Summary
Vitro Biopharma, Inc. quarterly Deferred Tax Assets, Operating Loss Carryforwards history and growth rate from Q3 2022 to Q3 2023.
  • Vitro Biopharma, Inc. Deferred Tax Assets, Operating Loss Carryforwards for the quarter ending October 31, 2023 was $3.07M, a 42.1% increase year-over-year.
Deferred Tax Assets, Operating Loss Carryforwards, Quarterly (USD)
Deferred Tax Assets, Operating Loss Carryforwards, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2023 $3.07M +$911K +42.1% Oct 31, 2023 10-K 2024-01-29
Q3 2022 $2.16M Oct 31, 2022 10-K 2024-01-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.